Bespoke Extracts (BSPK) posts revenue, margin gains but cash nearly gone; going concern flagged

Bespoke Extracts, Inc. (PINK: BSPK) - Quick internal read

What's happening inside: the company operates a Colorado marijuana-infused products manufacturing facility (The Joint Company). Revenue and gross profit improved in 2025, but cash is nearly depleted, liabilities are large, and management warns of substantial doubt about going concern. CEO Michael Feinsod also serves as principal financial officer and the company relies on debt and equity raises to survive.

Key points & statistics
* Q2 2025 sales: $390,553 vs Q2 2024 $278,163 (increase).
* Six months 2025 sales: $653,712 vs six months 2024 $538,591 (increase).
* Q2 2025 gross profit: $197,499 (gross margin ≈ 50.6%) vs Q2 2024 $106,117 (≈ 38.2%).
* Six months gross profit 2025: $308,278 (≈ 47.1%) vs 2024 $208,698 (≈ 38.8%).
* Q2 2025 net loss: $(205,106) or $(0.02) per share vs Q2 2024 $(260,895) or $(0.03).
* Six months net loss: $(465,627) or $(0.04) vs prior $(575,013) or $(0.06).
* Cash on hand (6/30/2025): $1,363 (down from $60,305 at 12/31/2024).
* Current liabilities: $1,485,466; accounts payable & accruals: $1,344,241. Working capital deficit: $1,330,730.
* Total liabilities: $2,806,344; total assets: $267,038; stockholders' deficit: $(2,539,306).
* Notes payable, net (secured & other): secured notes net $298,573; landlord note $169,000; related-party note $849,500.
* Interest expense (Q2 2025): $43,148 vs $10,652 in Q2 2024 (material increase).
* Warrants outstanding at 6/30/2025: 1,244,876 (weighted avg exercise $0.60); closing stock price used $0.114 on 6/30/2025.
* Shares outstanding (8/26/2025 disclosure): 11,153,220.
Positive aspects of the income statement
* Revenue growth year-over-year (Q2 and six-month periods) driven by increased pre-rolled joint sales and third‑party production services.
* Gross profit and gross margin improved substantially (Q2 margin rose to ~50.6% from ~38.2%), indicating better pricing mix or manufacturing efficiencies.
* Net loss narrowed both on a quarterly and six‑month basis; EPS loss improved from $(0.06) to $(0.04) year-to-date.
* SG&A benefited from lower stock‑based compensation in 2025 compared with 2024, helping reduce operating expense pressure on a six‑month basis. Negative aspects of the income statement and broader P&L-related risks
* Still operating at a loss: loss from operations Q2 2025 $(161,958) and six‑month loss $(407,296).
* SG&A remains very large relative to gross profit (total operating expenses Q2 $359,457 vs gross profit $197,499).
* Rapidly rising interest and financing costs: Q2 interest expense jumped to $43,148 (driven by new secured notes and amortization of debt discount).
* Cash burn persists: net cash used in operations for six months 2025 $(103,942); ending cash only $1,363 - financing risk is acute.
* Heavy current payables and a large related‑party note ($849,500) create short‑term liquidity pressure and potential related‑party dependency.
* Going concern: management explicitly states substantial doubt about the company's ability to continue for one year without additional financing; future equity or debt would dilute existing holders or be senior to common stock.
* Legal exposures: vendor lawsuit for ~$35,560 (fully reserved) and threatened wage/commission litigation from a former employee could add costs if successful.
* Concentration: operations and revenue are 100% Colorado; one customer was 13.9% of net accounts receivable at 6/30/2025 (concentration risk in receivables). Bottom line / near-term outlook
* Operationally the business shows improving sales and margins, indicating product and production traction in Colorado. However, financial health is weak: negligible cash, large payables, high interest burden and a working capital deficit. The company needs capital soon - likely debt or equity - which could dilute shareholders or increase leverage. Litigation and governance weaknesses (CEO is also CFO; material weaknesses in controls) add execution risk. Investors should treat BSPK as highly speculative and liquidity/concentration and going‑concern risks as primary near‑term concerns.